Kineon has helped pave the way for red light therapy, achieving massive success in providing relief from joint pain and inflammation for individuals.
To such an extent that the company has experienced rapid growth and will soon bring three new products to market.
One big thing: In its short three-year history, Kineon has relied on crowdfunding to support organic growth; however, additional product launches, new inventory, and further FDA clearances have made it challenging to continue on that path and necessitate additional fundraising efforts.
- Forrest Smith, the CEO and co-founder of Kineon, explained the expansion plans in an interview with the Morning Chalk Up: “We are raising $3 million, and that essentially will be going to the three product launches this year, and additional growth through our existing marketing channel.”
Remind me: Kineon makes science-backed red light therapy devices. The Move+ Pro is the flagship device the company offers, featuring three laser therapy modules that use a concentrated beam of light to target a specific area of the body.
The device can be worn anywhere on the body and uses red light therapy cycles to help stimulate healing of damaged tissues.
- In 2023, Kineon shipped 4.5 million products, and in 2024, they increased to 11 million.
The details: The three new products coming to market all serve different purposes.
The first is a four-channel laser device, an update to the current Move+ Pro, designed for deeper penetration.
Smith stated that the combined outcomes for this product are substantial, including significant increases in neurotransmitters such as serotonin and dopamine, as well as enhanced blood flow to the brain.
- “What that means from a daily basis for people is that essentially you’re healthier and more alert and more focused, in addition to not getting sick. It doesn’t counteract COVID or flu, but it can reduce how long you have it,” says Smith.
The second new product provides mitochondrial support functionality.
As Smith explained, one of the benefits of laser therapy is that it alleviates a bottleneck in cells’ ability to generate energy, boosting energy output by about 70%. However, even with laser therapy, this bottleneck isn’t eliminated. Therefore, Kineon has identified different ways to remove those barriers in mitochondrial energy production.
- “It’s amazing. You really feel it. It’s essentially a supplement to be used with laser therapy,” Smith added.
The last product Kineon plans to launch in Q4 is a gut-targeted device specifically using transcutaneous stimulation for the vagus nerve.
- “You unblock that highway between your gut and your brain, and you start seeing those neurotransmitter uplifts,” he said.
Kineon is still a young company and views 2025 as a pivotal year for growth. They expect to sell around $15 million worth of products this year, driven by strong interest. However, since they haven’t depended on fundraising, their marketing efforts have been somewhat limited.
- Part of the $3 million fundraising effort will be allocated towards expanding their marketing team to test different channels and optimize them over time.
While the company is seeking investors and looking to grow, its core mission is “to improve the quality of life for the largest number of people we can in the most measurable way we can,” says Smith.
Kineon approaches science and new technology in a holistic manner, focusing on helping individuals throughout their entire body, rather than just addressing one localized injury or ailment.
- “The gut and brain are such high leverage points for the human experience. If you can improve your cognition, such as reducing brain fog and enhancing cognitive processing, or avoid energy dips during the day. These are really, really big needle movers for people,” Smith said.
The bottom line: The company already has general investors, but is seeking health technology-specific companies that are invested in the products being produced.
- “What we’re looking for right now is who are the right value-added venture capital firms or family offices or investors in general that want to come in and do the due diligence, talk to us about the technology, and talk to us about the success that we’ve seen to date,” he adds.
Those interested in investing can reach out to Smith and Kineon here.
More CrossFit Stories
- Grit Over Everything – CrossFitter Danielle Fiorito’s Fight for a Kidney and a Future
- Relive Mat Fraser’s Most Iconic Workouts — The Moments That Made a Champion
- Training With Tia — Games Rookie Lucy McGonigle Learns From the Best at PRVN
Featured Image: @kineon_labs / Instagram
